ArticleThe Journal of biological chemistry2026
BAP1 and UTX are dispensable for transcription-driven Polycomb erasure but essential for enhancer establishment.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycomb group (PcG) proteins safeguard cell identity by maintaining target genes in a transcriptionally repressed state through depositing two histone marks, H2A lysine-119 ubiquitination (H2AK119ub1) and H3 lysine-27 trimethylation (H3K27me3). BAP1 and UTX are thought to erase these marks during transcription activation, but their exact roles remain unclear. Here, we observe a rapid loss of H2AK119ub1, followed by a reduction in H3K27me3 levels at promoters on transcription induction, coinciding with a swift dissociation of Polycomb repressive complexes (PRCs). With an acute degradation system, we show that neither BAP1 nor UTX is required for transcription activation or the dissolution of Polycomb group repressive marks, though BAP1 depletion leads to elevated steady-state H2AK119ub1 levels. Furthermore, while UTX regulates enhancer activation independently of its demethylase activity, BAP1 contributes to this process through a dual role: its scaffolding function supports MLL4 occupancy at nascent enhancers, whereas its catalytic activity restricts H2AK119ub1 accumulation that would otherwise impede enhancer maturation. Together, these findings establish that BAP1 and UTX are dispensable for transcription-driven erasure of Polycomb marks but are required for enhancer establishment, with BAP1 acting through coordinated scaffolding and catalytic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.